• Featured Product
  • KD/KO Validated

FABP4 Polyclonal antibody, PBS Only

FABP4 Polyclonal Antibody for WB, IHC, Indirect ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IHC, Indirect ELISA

Conjugate

Unconjugated

Cat no : 12802-1-PBS

Synonyms


☆対象製品が30%オフ!組換えタンパク質&免染用試薬 >>> キャンペーン実施中!


Tested Applications

Recommended dilution

ApplicationDilution
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Product Information

12802-1-PBS targets FABP4 in WB, IHC, Indirect ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen FABP4 fusion protein Ag3912 相同性解析による交差性が予測される生物種
Full Name fatty acid binding protein 4, adipocyte
Calculated molecular weight 132 aa, 15 kDa
Observed molecular weight 15 kDa
GenBank accession numberBC003672
Gene symbol FABP4
Gene ID (NCBI) 2167
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

Background Information

Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFκB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.